{"id":21162,"date":"2025-02-26T15:04:24","date_gmt":"2025-02-26T14:04:24","guid":{"rendered":"https:\/\/scandinavianacademicpress.no\/?post_type=open_access&#038;p=21162"},"modified":"2025-09-10T11:03:24","modified_gmt":"2025-09-10T09:03:24","slug":"kreftoverlevelse-pa-nye-mater","status":"publish","type":"open_access","link":"https:\/\/staging.forenteforlag.no\/scandinavian\/open_access\/kreftoverlevelse-pa-nye-mater\/","title":{"rendered":"Kreftoverlevelse p\u00e5 nye m\u00e5ter"},"content":{"rendered":"<p>Stadig flere av oss rammes av kreft. I 2022 var det i Norge 38 265 personer som fikk en kreftdiagnose, mer enn 1200 flere tilfeller enn i 2021 (Kreftregisteret, 2022). Hovedgrunnen til \u00f8kningen er at vi blir en eldre befolkning, og forekomsten er st\u00f8rst blant dem over 60 \u00e5r. De fire vanligste kreftformene prostata-, bryst-, lunge-, og tykktarmskreft utgj\u00f8r til sammen 43 prosent av alle krefttilfellene som ble diagnostisert i 2021 (Kreftregisteret, 2022). Samtidig gj\u00f8r framskritt innen diagnostikk og behandling sitt til at antallet som overlever kreft i verden, har \u00f8kt betraktelig. N\u00e5 overlever \u2013 heldigvis \u2013 n\u00e6r tre av fire, og behandlingsmetodene blir stadig bedre og mer persontilpasset. Ved utgangen av 2021 var det if\u00f8lge Kreftregisteret 316 145 menn og kvinner her til lands som har hatt kreft eller som lever med sin kreftsykdom. Det er over 100 000 flere enn for 10 \u00e5r siden. De omfattende og avanserte behandlingene kreftpasienter gjennomg\u00e5r, inneb\u00e6rer samtidig at mange lever med betydelige senskader og traumatiske erfaringer, erfaringer denne boka s\u00e6rlig g\u00e5r i dybden av.<\/p>\n","protected":false},"featured_media":21302,"template":"","fagomrade":[1773],"class_list":["post-21162","open_access","type-open_access","status-publish","has-post-thumbnail","hentry","fagomrade-helse"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Kreftoverlevelse p\u00e5 nye m\u00e5ter - Scandinavian Academic Press<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"nb_NO\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kreftoverlevelse p\u00e5 nye m\u00e5ter - Scandinavian Academic Press\" \/>\n<meta property=\"og:description\" content=\"Stadig flere av oss rammes av kreft. I 2022 var det i Norge 38 265 personer som fikk en kreftdiagnose, mer enn 1200 flere tilfeller enn i 2021 (Kreftregisteret, 2022). Hovedgrunnen til \u00f8kningen er at vi blir en eldre befolkning, og forekomsten er st\u00f8rst blant dem over 60 \u00e5r. De fire vanligste kreftformene prostata-, bryst-, [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/staging.forenteforlag.no\/scandinavian\/open_access\/kreftoverlevelse-pa-nye-mater\/\" \/>\n<meta property=\"og:site_name\" content=\"Scandinavian Academic Press\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ScandinavianAcademicPress\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-10T09:03:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/staging.forenteforlag.no\/scandinavian\/wp-content\/uploads\/sites\/7\/2025\/02\/03310_Kreftoverlevelse-pa-nye-mater_omslag_OA.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1087\" \/>\n\t<meta property=\"og:image:height\" content=\"1654\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ansl. lesetid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/staging.forenteforlag.no\/scandinavian\/open_access\/kreftoverlevelse-pa-nye-mater\/\",\"url\":\"https:\/\/staging.forenteforlag.no\/scandinavian\/open_access\/kreftoverlevelse-pa-nye-mater\/\",\"name\":\"Kreftoverlevelse p\u00e5 nye m\u00e5ter - Scandinavian Academic Press\",\"isPartOf\":{\"@id\":\"https:\/\/staging.forenteforlag.no\/scandinavian\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/staging.forenteforlag.no\/scandinavian\/open_access\/kreftoverlevelse-pa-nye-mater\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/staging.forenteforlag.no\/scandinavian\/open_access\/kreftoverlevelse-pa-nye-mater\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/staging.forenteforlag.no\/scandinavian\/wp-content\/uploads\/sites\/7\/2025\/02\/03310_Kreftoverlevelse-pa-nye-mater_omslag_OA.jpg\",\"datePublished\":\"2025-02-26T14:04:24+00:00\",\"dateModified\":\"2025-09-10T09:03:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/staging.forenteforlag.no\/scandinavian\/open_access\/kreftoverlevelse-pa-nye-mater\/#breadcrumb\"},\"inLanguage\":\"nb-NO\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/staging.forenteforlag.no\/scandinavian\/open_access\/kreftoverlevelse-pa-nye-mater\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"nb-NO\",\"@id\":\"https:\/\/staging.forenteforlag.no\/scandinavian\/open_access\/kreftoverlevelse-pa-nye-mater\/#primaryimage\",\"url\":\"https:\/\/staging.forenteforlag.no\/scandinavian\/wp-content\/uploads\/sites\/7\/2025\/02\/03310_Kreftoverlevelse-pa-nye-mater_omslag_OA.jpg\",\"contentUrl\":\"https:\/\/staging.forenteforlag.no\/scandinavian\/wp-content\/uploads\/sites\/7\/2025\/02\/03310_Kreftoverlevelse-pa-nye-mater_omslag_OA.jpg\",\"width\":1087,\"height\":1654},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/staging.forenteforlag.no\/scandinavian\/open_access\/kreftoverlevelse-pa-nye-mater\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hjem\",\"item\":\"https:\/\/staging.forenteforlag.no\/scandinavian\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kreftoverlevelse p\u00e5 nye m\u00e5ter\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.forenteforlag.no\/scandinavian\/#website\",\"url\":\"https:\/\/staging.forenteforlag.no\/scandinavian\/\",\"name\":\"Scandinavian Academic Press\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/staging.forenteforlag.no\/scandinavian\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.forenteforlag.no\/scandinavian\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nb-NO\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/staging.forenteforlag.no\/scandinavian\/#organization\",\"name\":\"Scandinavian Academic Press\",\"url\":\"https:\/\/staging.forenteforlag.no\/scandinavian\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nb-NO\",\"@id\":\"https:\/\/staging.forenteforlag.no\/scandinavian\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/staging.forenteforlag.no\/scandinavian\/wp-content\/uploads\/sites\/7\/2024\/09\/SAP_logo-1.svg\",\"contentUrl\":\"https:\/\/staging.forenteforlag.no\/scandinavian\/wp-content\/uploads\/sites\/7\/2024\/09\/SAP_logo-1.svg\",\"width\":4096,\"height\":1300,\"caption\":\"Scandinavian Academic Press\"},\"image\":{\"@id\":\"https:\/\/staging.forenteforlag.no\/scandinavian\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ScandinavianAcademicPress\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kreftoverlevelse p\u00e5 nye m\u00e5ter - Scandinavian Academic Press","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"nb_NO","og_type":"article","og_title":"Kreftoverlevelse p\u00e5 nye m\u00e5ter - Scandinavian Academic Press","og_description":"Stadig flere av oss rammes av kreft. I 2022 var det i Norge 38 265 personer som fikk en kreftdiagnose, mer enn 1200 flere tilfeller enn i 2021 (Kreftregisteret, 2022). Hovedgrunnen til \u00f8kningen er at vi blir en eldre befolkning, og forekomsten er st\u00f8rst blant dem over 60 \u00e5r. De fire vanligste kreftformene prostata-, bryst-, [&hellip;]","og_url":"https:\/\/staging.forenteforlag.no\/scandinavian\/open_access\/kreftoverlevelse-pa-nye-mater\/","og_site_name":"Scandinavian Academic Press","article_publisher":"https:\/\/www.facebook.com\/ScandinavianAcademicPress","article_modified_time":"2025-09-10T09:03:24+00:00","og_image":[{"width":1087,"height":1654,"url":"https:\/\/staging.forenteforlag.no\/scandinavian\/wp-content\/uploads\/sites\/7\/2025\/02\/03310_Kreftoverlevelse-pa-nye-mater_omslag_OA.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Ansl. lesetid":"2 minutter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/staging.forenteforlag.no\/scandinavian\/open_access\/kreftoverlevelse-pa-nye-mater\/","url":"https:\/\/staging.forenteforlag.no\/scandinavian\/open_access\/kreftoverlevelse-pa-nye-mater\/","name":"Kreftoverlevelse p\u00e5 nye m\u00e5ter - Scandinavian Academic Press","isPartOf":{"@id":"https:\/\/staging.forenteforlag.no\/scandinavian\/#website"},"primaryImageOfPage":{"@id":"https:\/\/staging.forenteforlag.no\/scandinavian\/open_access\/kreftoverlevelse-pa-nye-mater\/#primaryimage"},"image":{"@id":"https:\/\/staging.forenteforlag.no\/scandinavian\/open_access\/kreftoverlevelse-pa-nye-mater\/#primaryimage"},"thumbnailUrl":"https:\/\/staging.forenteforlag.no\/scandinavian\/wp-content\/uploads\/sites\/7\/2025\/02\/03310_Kreftoverlevelse-pa-nye-mater_omslag_OA.jpg","datePublished":"2025-02-26T14:04:24+00:00","dateModified":"2025-09-10T09:03:24+00:00","breadcrumb":{"@id":"https:\/\/staging.forenteforlag.no\/scandinavian\/open_access\/kreftoverlevelse-pa-nye-mater\/#breadcrumb"},"inLanguage":"nb-NO","potentialAction":[{"@type":"ReadAction","target":["https:\/\/staging.forenteforlag.no\/scandinavian\/open_access\/kreftoverlevelse-pa-nye-mater\/"]}]},{"@type":"ImageObject","inLanguage":"nb-NO","@id":"https:\/\/staging.forenteforlag.no\/scandinavian\/open_access\/kreftoverlevelse-pa-nye-mater\/#primaryimage","url":"https:\/\/staging.forenteforlag.no\/scandinavian\/wp-content\/uploads\/sites\/7\/2025\/02\/03310_Kreftoverlevelse-pa-nye-mater_omslag_OA.jpg","contentUrl":"https:\/\/staging.forenteforlag.no\/scandinavian\/wp-content\/uploads\/sites\/7\/2025\/02\/03310_Kreftoverlevelse-pa-nye-mater_omslag_OA.jpg","width":1087,"height":1654},{"@type":"BreadcrumbList","@id":"https:\/\/staging.forenteforlag.no\/scandinavian\/open_access\/kreftoverlevelse-pa-nye-mater\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hjem","item":"https:\/\/staging.forenteforlag.no\/scandinavian\/"},{"@type":"ListItem","position":2,"name":"Kreftoverlevelse p\u00e5 nye m\u00e5ter"}]},{"@type":"WebSite","@id":"https:\/\/staging.forenteforlag.no\/scandinavian\/#website","url":"https:\/\/staging.forenteforlag.no\/scandinavian\/","name":"Scandinavian Academic Press","description":"","publisher":{"@id":"https:\/\/staging.forenteforlag.no\/scandinavian\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.forenteforlag.no\/scandinavian\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nb-NO"},{"@type":"Organization","@id":"https:\/\/staging.forenteforlag.no\/scandinavian\/#organization","name":"Scandinavian Academic Press","url":"https:\/\/staging.forenteforlag.no\/scandinavian\/","logo":{"@type":"ImageObject","inLanguage":"nb-NO","@id":"https:\/\/staging.forenteforlag.no\/scandinavian\/#\/schema\/logo\/image\/","url":"https:\/\/staging.forenteforlag.no\/scandinavian\/wp-content\/uploads\/sites\/7\/2024\/09\/SAP_logo-1.svg","contentUrl":"https:\/\/staging.forenteforlag.no\/scandinavian\/wp-content\/uploads\/sites\/7\/2024\/09\/SAP_logo-1.svg","width":4096,"height":1300,"caption":"Scandinavian Academic Press"},"image":{"@id":"https:\/\/staging.forenteforlag.no\/scandinavian\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ScandinavianAcademicPress"]}]}},"_links":{"self":[{"href":"https:\/\/staging.forenteforlag.no\/scandinavian\/wp-json\/wp\/v2\/open_access\/21162","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/staging.forenteforlag.no\/scandinavian\/wp-json\/wp\/v2\/open_access"}],"about":[{"href":"https:\/\/staging.forenteforlag.no\/scandinavian\/wp-json\/wp\/v2\/types\/open_access"}],"version-history":[{"count":4,"href":"https:\/\/staging.forenteforlag.no\/scandinavian\/wp-json\/wp\/v2\/open_access\/21162\/revisions"}],"predecessor-version":[{"id":22521,"href":"https:\/\/staging.forenteforlag.no\/scandinavian\/wp-json\/wp\/v2\/open_access\/21162\/revisions\/22521"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/staging.forenteforlag.no\/scandinavian\/wp-json\/wp\/v2\/media\/21302"}],"wp:attachment":[{"href":"https:\/\/staging.forenteforlag.no\/scandinavian\/wp-json\/wp\/v2\/media?parent=21162"}],"wp:term":[{"taxonomy":"fagomrade","embeddable":true,"href":"https:\/\/staging.forenteforlag.no\/scandinavian\/wp-json\/wp\/v2\/fagomrade?post=21162"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}